This suggests that the most modern lung cancer therapy—the immune checkpoint inhibition of PD-L1—can be enhanced with PRMT5 inhibitors, supporting the development of PRMT5-targeted therapies and the application of combined therapies. Here, PRMT5 is linked to lung carcinoma.